发明名称 Aryl-substituted tricyclic sulfonamides as methionyl aminopeptidase 2 modulators
摘要 The invention provides tricyclic sulfonamide compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2. For example, the invention relates in part to tricyclic sulfonamide compounds represented by Formula I:;or pharmaceutically acceptable salts or stereoisomers thereof, wherein A, B, D, RA1, RA2, Y, X, and n are as defined herein.
申请公布号 US9187494(B2) 申请公布日期 2015.11.17
申请号 US201214116026 申请日期 2012.05.07
申请人 Zafgen, Inc. 发明人 Cramp Susan Mary;Dyke Hazel Joan;Pallin Thomas David;Zahler Robert
分类号 A61K31/10;C07C317/14;C07D498/04;C07D471/04;C07D487/04 主分类号 A61K31/10
代理机构 Goodwin Procter LLP 代理人 Goodwin Procter LLP
主权项 1. A tricyclic compound represented by:and wherein: A is phenyl;RA1 is selected, independently for each occurrence, from the group consisting of: hydrogen, hydroxy, cyano, halogen, C1-4alkyl, and C1-3alkoxy; wherein C1-4alkyl or C1-3alkoxy may be optionally substituted by one or more fluorines;n is 1 or 2;RA2 is selected from the group consisting of: hydrogen, RiRjN—, heterocyclyl, heterocyclyloxy, and heterocyclyl-(NRa)—; wherein said heterocyclyl may optionally be substituted by one or more substituents selected from Rg; and wherein if said heterocyclyl contains a —NH moiety that nitrogen may optionally be substituted by one or more groups Rh; orRA2 may be selected from the group consisting of: C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, C1-6alkoxy, C3-6alkenyloxy, C3-6alkynyloxy, C3-6cycloalkoxy, C1-6alkyl-S(O)w— (wherein w is 0, 1 or 2), C1-6alkyl-N(Ra)—, C1-6alkyl-N(Ra)-carbonyl-, C1-6alkylcarbonyl-N(Ra)—, C1-6alkyl-N(Ra)-carbonyl-N(Ra)—, C1-6alkyl-N(Ra)—SO2—, C1-6alkyl-SO2—N(Ra)—, C1-6alkoxycarbonyl-N(Ra)—, C1-6alkylcarbonyl-N(Ra)—C1-6alkyl-, C1-6alkyl-N(Ra)-carbonyl-C1-6alkyl-, and C1-6alkoxyC1-6alkyl-; wherein C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, C1-6alkoxy, C3-6alkenyloxy, C3-6alkynyloxy, C3-6cycloalkoxy, C1-6alkyl-S(O)w—, C1-6alkyl-N(Ra)—, C1-6alkyl-N(Ra)-carbonyl-, C1-6alkylcarbonyl-N(Ra)—, C1-6alkyl-N(Ra)-carbonyl-N(Ra)—, C1-6alkyl-N(Ra)—SO2—, C1-6alkyl-SO2—N(Ra)—, C1-6alkoxycarbonyl-N(Ra)—, C1-6alkylcarbonyl-N(Ra)C1-6alkyl-, C1-6alkyl-N(Ra)-carbonyl-C1-6alkyl-, C1-6alkoxy-C1-6alkyl may optionally be substituted by RP, phenyl, phenoxy, heteroaryl, heteroaryloxy, heteroaryl-(NRa)—, heterocyclyl, heterocyclyloxy or heterocyclyl-N(Ra)—; and wherein said heteroaryl or phenyl may optionally be substituted with one or more substituents selected from Rf; and wherein said heterocyclyl may optionally be substituted by one or more substituents selected from Rg; and wherein if said heterocyclyl contains a —NH moiety that nitrogen may optionally be substituted by one or more groups Rh;Ra and Rb are independently selected, for each occurrence, from the group consisting of: hydrogen and C1-3alkyl; wherein C1-3alkyl may optionally be substituted by one or more substituents selected from the group consisting of: fluorine, cyano, oxo, and hydroxy;or Ra and Rb, together with the nitrogen to which they are attached, may form a 4-6 membered heterocyclic ring which may have an additional heteroatom selected from O, S, or N; wherein the 4-6 membered heterocyclic ring may optionally be substituted on carbon by one or more substituents selected from the group consisting of: fluorine, cyano, oxo, and hydroxy;Rf is independently selected, for each occurrence, from the group consisting of: RP, hydrogen, C1-6alkyl, C3-6cycloalkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, C1-6alkoxy, C1-6alkyl-S(O)w— (wherein w is 0, 1 or 2), C1-6alkylcarbonl-N(Ra)—, and C1-6alkoxycarbonyl-N(Ra)—; wherein C1-6alkyl, C3-6cycloalkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, C1-6alkoxy, C1-6alkyl-S(O)w—, C1-6alkylcarbonyl-N(Ra)—, or C1-6alkoxycarbonyl-N(Ra)— may be optionally substituted by one or more substituents selected from RP;Rg is independently selected for each occurrence from the group consisting of: RP, hydrogen, oxo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, C1-6alkoxy, C1-6alkyl-S(O)w— (wherein w is 0, 1 or 2), C1-6alkylcarbonyl-N(Ra)—, and C1-6alkoxycarbonyl-N(Ra)—; wherein C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-3cycloalkyl, C1-6alkoxy, C1-6 alkyl-S(O)w—, C1-6alkylcarbonyl-N(Ra)—, or C1-6alkoxycarbonyl-N(Ra)— may be optionally substituted by one or more substituents selected from RP;Rh is independently selected for each occurrence from the group consisting of: hydrogen, C1-6alkyl, C3-6alkenyl, C3-6alkynyl, C3-6cycloalkyl, C1-6alkyl-S(O)2—, C1-6alkoxycarbonyl-, RiRjN-carbonyl-, RiRjN—SO2—; wherein C1-6alkyl, C3-6alkenyl, C3-6alkynyl, C3-6cycloalkyl, C1-6alkyl-S(O)2—, C1-6alkylcarbonyl- may optionally be substituted by one or more substituents selected from RP;Ri and Rj are selected independently for each occurrence from the group consisting of: hydrogen, C1-4alkyl and C3-6cycloalkyl; wherein C1-4alkyl and C3-6cycloalkyl may be optionally substituted by one or more substituents selected from fluorine, hydroxyl, cyano, RaRbN—, RaRbN-carbonyl-, C1-3alkoxy;or Ri and Rj taken together with the nitrogen to which they are attached may form a 4-7 membered heterocyclic ring which may have an additional heteroatom selected from O, S, or N, optionally substituted on carbon by one or more substituents selected from the group consisting of: fluorine, hydroxyl, oxo, cyano, C1-6alkyl, C1-6alkoxy, RaRbN—, RaRbN—SO2—, and RaRbN-carbonyl-; and wherein said C1-6alkyl or C1-6alkoxy may optionally be substituted by fluorine, hydroxyl or cyano; and optionally substituted on nitrogen by one or more substituents selected from the group consisting of: C1-6alkyl, RaRbN-carbonyl-; and wherein said C1-6alkyl may be optionally substituted by fluorine, hydroxyl, cyano;RP is independently selected, for each occurrence, from the group consisting of: halogen, hydroxyl, cyano, C1-6alkoxy, RiRjN—, RiRjN-carbonyl-, RiRjN—SO2—, RiRjN-carbonyl-N(Ra)—;and pharmaceutically acceptable salts and stereoisomers thereof.
地址 Boston MA US